Rosetta Receives Clearance to Sell miRNA Diagnostics in NY State

With the approval, Rosetta can now sell its suite of three microRNA-based tests in all 50 states.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.